Mark Velleca

1.3k citations

18 papers · 1.1k indexed · h-index 10

Impact in

Molecular Biology top 10%
- Advanced Biosensing Techniques and Applications
- Advanced biosensing and bioanalysis techniques
- Muscle Physiology and Disorders
- RNA Research and Splicing
Radiology, Nuclear Medicine and Imaging top 10%
- Monoclonal and Polyclonal Antibodies Research

Papers in ⓘ

Molecular Biology 15
- RNA and protein synthesis mechanisms 3
- RNA Research and Splicing 2
- 14-3-3 protein interactions 2
- Cancer-related gene regulation 2
Oncology 4
- Cancer Treatment and Pharmacology 3

Co-authors: Stephen F. Kingsmore (1 shared paper)Velizar T. Tchernev (1 shared paper)Scott Roberts (1 shared paper)Zhimin Zhou (1 shared paper)Minjuan Wang (1 shared paper)Barry Schweitzer (1 shared paper)Qin Fu (1 shared paper)Brian G. Grimwade (1 shared paper)
Journals: Cancer Research (2 papers)The Journal of Cell Biology (2 papers)Molecular and Cellular Biology (2 papers)Assay and Drug Development Technologies (1 paper)Transfusion (1 paper)
Partner nations: United States India United Kingdom

In The Last Decade

Mark Velleca

18 papers receiving 1.1k citations

Peers

Countries citing papers authored by Mark Velleca

Since Specialization

Citations

This map shows the geographic impact of Mark Velleca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Velleca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Velleca more than expected).

Fields of papers citing papers by Mark Velleca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Velleca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Velleca. The network helps show where Mark Velleca may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Velleca, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Velleca Line = papers co-authored together Mark Velleca links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Multiplexed protein profiling on microarrays by rolling-circle amplification Nature Biotechnology ·Barry Schweitzer, Scott Roberts, Brian G. Grimwade, Weiping Shao, Minjuan Wang, Qin Fu, Quiping Shu, Isabelle Laroche, Zhimin Zhou, Velizar T. Tchernev, Jason Christiansen, Mark Velleca, Stephen F. Kingsmore	2002	461
2	Type 2X-myosin heavy chain is coded by a muscle fiber type-specific and developmentally regulated gene. The Journal of Cell Biology ·Celise Denardi, Simonetta Ausoni, Paolo Moretti, Luisa Gorza, Mark Velleca, M Buckingham, Stefano Schiaffino	1993	194
3	Molecular cloning and tissue distribution of PHAS-I, an intracellular target for insulin and growth factors. Proceedings of the National Academy of Sciences ·C. Hu, Stephen C. Pang, Xiuying Kong, Mark Velleca, John C. Lawrence	1994	119
4	Large-Scale Culture and Selective Maturation of Human Langerhans Cells from Granulocyte Colony-Stimulating Factor-Mobilized CD34+ Progenitors The Journal of Immunology ·Evelina Gatti, Mark Velleca, Barbara Biedermann, Weilie Ma, Juli Unternaehrer, Melanie Ebersold, Ruslan Medzhitov, Jordan S. Pober, Ira Mellman	2000	89
5	Molecular cloning and sequence analysis of the Chlamydomonas gene coding for radial spoke protein 3: flagellar mutation pf-14 is an ochre allele. The Journal of Cell Biology ·B D Williams, Mark Velleca, Alice M. Curry, Joel L. Rosenbaum	1989	85
6	Novel chemical genetic approaches to the discovery of signal transduction inhibitors Drug Discovery Today ·Kevan M. Shokat, Mark Velleca	2002	62
7	A novel synapse-associated noncoding RNA. Molecular and Cellular Biology ·Mark Velleca, Mia Wallace, John P. Merlie	1994	47
8	A Novel Synapse-Associated Noncoding RNA Molecular and Cellular Biology ·Mark Velleca, Mia Wallace, John P. Merlie	1994	15
9	Genetically Engineered Mouse Models for Drug Discovery: New Chemical Genetic Approaches Current Drug Discovery Technologies ·Susanne Heck, Xiaobing Qian, Mark Velleca	2004	11
10	Ex vivo evaluation of PBMNCs collected with a new cell separator Transfusion ·Edward L. Snyder, Lynn O’Donnell, Thomas J. Dengler, Gregory J. Pomper, Mark Velleca, Dorothy M. Dincecco, Laurene L. Baril, Kyungyoon Min, Maria Gudino, Jeffrey R. Bender	2001	10
11	Synapse-specific gene expression Gerald C. Chu, Mark Velleca, John P. Merlie	1995	7
12	Abstract B11: Preclinical and preliminary phase 1 trial results of JI-101: A novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFR Molecular Cancer Therapeutics ·Mark Velleca, David R. Brittelli, Lisa Elkin, Udo Klein, Scott A. Mitchell, Dapeng Qian, Xiaobing Qian, Sreesha Srinivasa, Thomas Stephan, Raman Govindarajan, Warren C. Stern, Michael S. Gordon, Sunil Sharma, Linda Miller	2009	5
13	Abstract 3286: Oral bioavailability, permeability, CYP profiling, identification of major metabolites, tissue distribution and excretion profile of a novel triple kinase inhibitor, JI-101 in rats Cancer Research ·Sandip Gurav, Ravindranath Reddy Gilibili, Sherine Jeniffer, Mohd Zainuddin, Sanjeev Giri, Raman Govindrajan, Mark Velleca, Srinivas Nuggehally, Ramesh Mullangi	2011	3
14	Abstract 17: Preclinical and phase 1 trial results of JI-101, a novel, oral tyrosine kinase inhibitor that selectively targets VEGFR2, EphB4, and PDGFRβ Cancer Research ·Mark Velleca, Linda Miller, Sunil Sharma, Michael S. Gordon, David R. Brittelli, Lisa Elkin, Raman Govindarajan, Udo Klein, Scott A. Mitchell, N. Nandhagopal, Dapeng Qian, Xiaobing Qian, Thomas Stephen, Sreesha Srinivasa, Warren C. Stern	2010	3
15	Chemical Genetic Transcriptional Fingerprinting for Selectivity Profiling of Kinase Inhibitors Assay and Drug Development Technologies ·Shan Jiang, Julie DiPaolo, Kevin Currie, Scott Alderucci, Arun Ramamurthy, Johnny Peppers, Xiaobing Qian, Dapeng Qian, Tarif Awad, Mark Velleca, J. Andrew Whitney	2007	2
16	400 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ European Journal of Cancer Supplements ·Michael S. Gordon, Shivani Sharma, L. Miller, N. R. Srinivas, Mukesh Sahu, Raman Govindarajan, Ramesh Mullangi, Mark Velleca, David R. Brittelli	2010	2
17	196 PK/PD models using a selective Ephrin B4 inhibitor JI-101 alone and in combination with other targeted agents and chemotherapy: Results of preclinical and ex-vivo studies European Journal of Cancer Supplements ·Santosh Kumar Sharma, Ramesh Mullangi, Matthew Wade, Sandip Gurav, Sujith V Sajja, Deepa Shankar, N. Srinivas, R. Govindarajan, Lance D. Miller, Mark Velleca	2010	2
18	Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics Current Proteomics ·Benjamin K. Benton, Christian Rommel, Mark Velleca, Christian Pasquali	2004	1

About Mark Velleca

Mark Velleca is a scholar working on Molecular Biology, Oncology, Hematology, Cell Biology and Immunology, having authored 18 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (3 papers), RNA and protein synthesis mechanisms (3 papers), RNA Research and Splicing (2 papers), T-cell and B-cell Immunology (2 papers), Immune Cell Function and Interaction (2 papers), 14-3-3 protein interactions (2 papers), Cancer-related gene regulation (2 papers) and Cellular transport and secretion (2 papers). The work is most often cited by research in Molecular Biology (937 citations), Radiology, Nuclear Medicine and Imaging (175 citations), Cell Biology (100 citations), Immunology (125 citations) and Biomedical Engineering (225 citations). Mark Velleca has collaborated with scholars based in United States, India and United Kingdom. Frequent co-authors include Stephen F. Kingsmore, Velizar T. Tchernev, Scott Roberts, Zhimin Zhou, Minjuan Wang, Barry Schweitzer, Qin Fu, Brian G. Grimwade, Jason Christiansen and Kevan M. Shokat. Their work appears in journals such as Cancer Research, The Journal of Cell Biology, Molecular and Cellular Biology, Assay and Drug Development Technologies and Transfusion.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact